Biocontrol of Alternaria alternata YZU, a causal of stem end rot disease on pitaya, with soil phosphate solubilizing bacteria

Stem end rot is the most destructive disease caused by Alternaria alternata YZU in pitaya-growing regions of Vietnam. This study was conducted to characterize antagonistic phosphate-solubilizing bacteria (PSB) from rhizosphere soil for their biocontrol activities against A. alternata YZU and evaluate the effect of temperature, pH, and water activity on that antagonism. Among seven PSB isolated from 45 rhizosphere soil samples, PSB31 (identified as Bacillus sp. strain IMAU61039, Accession number: MF803700.1) exhibited the highest antagonistic activity against A. alternata YZU with an average inhibition diameter of 0.65 ± 0.05 cm. The results also show that the strain PSB31 controlled the mycelial growth of A. alternata YZU by secreting antifungal metabolites. The most potent inhibitory activity was identified under in vitro conditions of 25 °C, pH 7, and aw 1. The isolated PSB31 could be a potential biological control agent against A. alternata YZU

Association of pre-chemotherapy peripheral blood pro-inflammatory and coagulation factors with reduced relative dose intensity in women with breast cancer

Abstract Background Chemotherapy decreases the risk of relapse and mortality in early-stage breast cancer (BC), but it comes with the risk of toxicity. Chemotherapy efficacy depends on relative dose intensity (RDI), and an RDI < 85% is associated with worse overall survival. The pro-inflammatory (interleukin (IL)-6, C-reactive protein (CRP)) and coagulation factors (D-dimer) serve as biomarkers of aging. The purpose of this study is to determine if these biomarkers are associated with reduced RDI in women with stage I–III BC. Methods This study enrolled women with stage I–III BC. Prior to adjuvant or neoadjuvant chemotherapy, peripheral blood was collected for biomarker measurement. Dose reductions and delays were captured and utilized to calculate the RDI delivered. Univariate and multivariate analyses were performed to describe the association between pre-chemotherapy IL-6, CRP, and D-dimer levels and an RDI < 85%, controlling for relevant tumor and patient factors (age, stage, receptor status, chemotherapy regimen, and pre-chemotherapy physical function and comorbidity). Results A total of 159 patients (mean age 58 years, range 30–81, SD 11.3) with stage I–III BC were enrolled. An RDI < 85% occurred in 22.6% (N = 36) of patients and was associated with higher pre-chemotherapy IL-6 (OR 1.14, 95% CI 1.04–1.25; p = 0.006) and D-dimer (OR 2.32, 95% CI 1.27–4.24; p = 0.006) levels, increased age (p = 0.001), increased number of comorbidities (p = 0.01), and decreased physical function by the Medical Outcomes Survey Activities of Daily Living (ADL) Scale (p = 0.009) in univariate analysis. A multivariate model, including two biomarkers (IL-6 and D-dimer), age, ADL, BC stage, and chemotherapy regimen, demonstrated a significant association between the increased biomarkers and reduced RDI < 85% (OR 2.54; p = 0.04). Conclusions Increased pre-chemotherapy biomarkers of aging (IL-6 and D-dimer) are associated with reduced RDI (<85%). Future studies are underway to validate these findings. Trial registration ClinicalTrials.gov, NCT01030250 . Registered on 3 November 2016

Additional file 1: Table S1. of Association of pre-chemotherapy peripheral blood pro-inflammatory and coagulation factors with reduced relative dose intensity in women with breast cancer

Biomarkers measurement in neo-adjuvant-treated vs. adjuvant-treated patients. (DOC 39 kb

Additional file 1: Table S1. of Association of pre-chemotherapy peripheral blood pro-inflammatory and coagulation factors with reduced relative dose intensity in women with breast cancer

Biomarkers measurement in neo-adjuvant-treated vs. adjuvant-treated patients. (DOC 39 kb

Additional file 2: Table S2. of Association of pre-chemotherapy peripheral blood pro-inflammatory and coagulation factors with reduced relative dose intensity in women with breast cancer

Biomarkers and RDI < 85% in overall patients vs. adjuvant patients. (DOC 31 kb